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Abstract: Multiple molecular, cellular, structural and functional changes occur in the brain during aging. Neural cells may respond to 
these changes adaptively by employing multiple mechanisms in order to maintain the integrity of nerve cell circuits and to facilitate 
responses to environmental demands. Otherwise, they may succumb to neurodegenerative cascades that result in disorders such as 
Alzheimer’s and Parkinson’s diseases. An important role in this balancement is played by neurotrophic factors, which are central to many 
aspects of nervous system function since they regulate the development, maintenance and survival of neurons and neuron-supporting 
cells such as glia and oligodendrocytes. A vast amount of evidence indicates that alterations in levels of neurotrophic factors or their 
receptors can lead to neuronal death and contribute to aging as well as to the pathogenesis of diseases of abnormal trophic support (such 
as neurodegenerative diseases and depression) and diseases of abnormal excitability (such as epilepsy and central pain sensitization). 
Cellular and molecular mechanisms by which neurotrophic factors may influence cell survival and excitability are also critically 
examined to provide novel concepts and targets for the treatment of psysiological changes bearing detrimental functional alterations and 
of different diseases affecting the central nervous system during aging. 
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BRAIN CHANGES DURING AGING 
 It is well established that healthy aging is accompanied by 
multiple changes in many brain regions and functional decline in a 
number of cognitive domains [1]. Normal changes in brain 
physiology occur over time and can gradually result in slower 
information processing and alterations in memory function. In 
particular, most prominent among age-related brain changes are 
slowing of cognitive processing speed, diminished ability to acquire 
and recall new information, increased difficulty ignoring 
distractions, focusing attention and recalling to mind appropriate 
words. These age-related changes are thought to be the result of 
ongoing physiological processes that would begin in youth, but, 
depending on factors such as genetic background and lifestyle, 
generally become evident and start to affect cognition in middle age 
and beyond.  
 In spite of a large body of descriptive work on the cellular, 
structural and functional changes occuring during brain aging, a 
general view is lacking and the molecular mechanisms underlying 
loss of neuronal plasticity, perceived as the key element of brain 
aging, are to date largely unknown [2]. The described age-related 
changes of the human brain include a decline in total brain volume 
and weight, especially in the frontal lobes and hippocampus, 
regions essential for learning and memory, associated with cortical 
thinning, gyral atrophy and white-matter degradation [3]. These 
changes may be due to nerve cell loss or cell shrinkage and, among 
the various brain areas, hippocampus seems to be particularly 
vulnerable [4]. However, evidence suggest that neuronal loss 
observed in some brain regions could be compensated by expansion 
of dendritic arbors and increased synaptogenesis in the remaining 
neurons [5]. Moreover, neuronal changes may also occur, with a 
decline in neurotransmitters and receptors, a decrease in the number 
of synapses and a deterioration of axons and dendrites, which 
contribute to the impairment of neuronal function [6].  
 Changes in the cellular structure of the brain and the functions 
of its neuronal circuits are controlled by a complex array of inter-
cellular signalling molecules and intracellular signal transduction 
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pathways. Several such cellular signal transduction systems are 
altered during brain aging. Among neurotransmitter systems, 
dopaminergic signalling appears to be consistently altered during 
aging with a progressive decrease in signalling via the D2 subtype 
of receptor [7-8]. Furthermore, altered serotonin (5-HT) signalling 
has been recently considered as another contributing factor to aging 
[8-9]. Examples of widely used intracellular signalling mechanisms 
affected by aging include protein phosphorylation (alterations in 
kinases and phosphatases) [10], cellular calcium homeostasis [11-
12], and gene transcription [13-14]. Within this context, the middle 
age and aged groups show an upregulation of cortical genes and 
pathways related to oxidative damage and inflammation, and 
downregulation of genes associated with DNA repair and synaptic 
function, particularly for vesicular transport and neurotransmission 
[14,15-17]. In addition to signalling pathways, cellular systems that 
regulate protein folding and degradation are altered in brain cells 
during aging [18]. These kinds of alterations that occur during 
normal aging may set the stage for neurodegenerative cascades that 
result in disorders such as Alzheimer’s and Parkinson’s diseases, 
that in turn may be triggered by particular genetic predispositions or 
environmental factors, while other age-related changes may 
represent adaptive protective responses to the aging process. 
 In regard to the molecular and cellular mechanisms that 
determine whether brain aging occurs successfully or manifests 
dysfunction or disease, the major classes of signalling molecules 
important in brain aging include neurotrophic factors, neuro-
transmitters, cytokines and steroids. 
 In particular, an important role in balancing protective/ 
neurodegenerative processes is played by neurotrophic factors, 
which are central to many aspects of nervous system function since 
they regulate the development, maintenance and survival of neurons 
and neuron-supporting cells such as glia and oligodendrocytes. 
NEUROTROPHIC FACTORS 
 Neurotrophic factors (NTFs) are diffusible peptides secreted 
from neurons and neuron-supporting cells. NTFs belong to several 
superfamilies of structurally and functionally related molecules: 1) 
neurotrophins, including nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4; 2) 
transforming growth factor (TGF)-? superfamily, which includes 
among others the glial-cell-line-derived neurotrophic factor 
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(GDNF); 3) neurokine superfamily and 4) non-neuronal factors (for 
a more detailed list, see Table 1).  
 NTFs have been shown to promote the survival of specific 
populations of brain neurons under experimental conditions 
relevant to brain aging and neurodegenerative disorders [19]. NTFs 
exert their effects on the development and function of neurons by 
binding to cell surface receptors possessing intrinsic tyrosine kinase 
activity, in turn activating downstream kinases including the phos-
phatidylinositol-3-kinase, protein kinase C?, and the mitogen-
activated protein kinase, as well as several small G-proteins, inclu-
Table 1. Classification of the Neurotrophic Factors Superfamilies in Humans 
Neurotrophic superfamily factors Family/Member Sub-member 
NGF   
BDNF  
NT-3  
NGF superfamily 
NT-4  
GDNF 
Neurturin 
Artemin  
GDNF family  
Persephin 
TGF?1 
TGF?2 TGF? family  
TGF?3 
Bone Morphogenetic Protein 1  
Bone Morphogenetic Protein 2  
Bone Morphogenetic Protein 3  
Bone Morphogenetic Protein 4  
Bone Morphogenetic Protein 5  
Bone Morphogenetic Protein 6  
Bone Morphogenetic Protein 71  
Bone Morphogenetic Protein 8a  
Bone Morphogenetic Protein 8b  
Bone Morphogenetic Protein 10  
TGF? superfamily 
Bone morphogenetic protein family 
Bone Morphogenetic Protein 15  
CNTF   
Interleukin-6  
Interleukin-11  
Leukemia inhibitory factor   
Oncostatin M   
Cardiotrophin-1  
Neurokine superfamily 
Granulocyte colony-stimulating factor  
IGF-1  
Acidic fibroblast growth factor  
Basic fibroblast growth factor   
Non-neuronal factors 
Epidermal growth factor  
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ding Rap-1 and the Cdc-42-Rac-Rho family [20]. As a conse-
quence, one or more transcription factors including AP1, NF-?B 
and FOXO are activated and ultimately the expression of genes that 
encode proteins involved in regulating neuronal survival, 
differentiation and plasticity is induced.  
 One or more of these various growth factors and mechanisms 
may fail during development, neuronal repair and aging causing 
disease including, but not limited to, neurodegenerative illnesses. 
Indeed, their abnormal trophic support for selective neuronal 
populations has been proposed to contribute to the pathogenesis of 
depression, neurodegenerative disorders such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), Huntington’s disease 
(HD), amyotrophic lateral sclerosis (ALS) and also aging [21-29]; 
in parallel, alterations in levels of NTFs or their receptors have been 
correlated to diseases of abnormal excitability such as epilepsy and 
central pain sensitization [29-30]. 
 This review is focused on some NTFs for which data of recent 
human clinical studies and trials are available unraveling their 
therapeutic potential in a variety of diseases states and aging. In 
particular, we included NGF, BDNF, GDNF, insulin-like growth 
factor I (IGF-I) and ciliary neurotrophic factor (CNTF). 
NEUROTROPHINS 
 As previously mentioned, neurotrophins include NGF, BDNF, 
NT-3 and NT-4. Neurotrophin receptors are typically present in the 
neurites (axons and dendrites) of growing neurons during deve-
lopment, and in pre and postsynaptic terminals of neurons in the 
mature nervous system. Neurotrophins exert their effects by 
interacting with two structurally unrelated receptors, the tyrosine 
receptor kinase (Trk) and p75, which differ for ligand specificity 
and signal transduction activities. Neurotrophins are synthesized as 
precursors with major dimension and then cleaved by furin and 
proconvertase to produce mature protein. In their active cleaved 
form, each neurotrophin selectively activates one of three types of 
Trk receptors. NGF binds the TrkA receptor, BDNF and NT-4 bind 
to TrkB, and NT-3 binds TrkC [31]. All four neurotrophins can 
bind to the low-affinity p75 neurotrophin receptor. Binding of 
neurotrophins to their Trk receptors causes signalling events which 
promote neuron survival, whereas activation of the p75 neuro-
trophin receptor pathway triggers apoptosis and cell death [32]. 
Proneurotrophins bind to the receptor sortilin (also known as the 
neurotensin-3 receptor) [33] and p75, which, like TrkA and p75, 
interact to form an high-affinity binding site [34], which appears to 
mediate the neurotoxic effects of proNGF [34] and also proBDNF 
[35]. Thus, the role of proneurotrophins and neurotrophins appears 
to be opposite: neurotrophins maintain survival and function to 
certain neuronal populations, whereas proneurotrophins trigger cell 
death through p75. 
NERVE GROWTH FACTOR-NGF 
 NGF, the first member of neurotrophin family, supports 
neuronal survival during development and modulates neuronal 
functions throughout adulthood. The highest NGF protein levels 
have been observed in the hyppocampus, cortex and olfactory bulb, 
where most NGF-producing cells are neurons [36]. In central 
nervous system (CNS), aging and age-related cognitive impair-
ments are known to correlate with the cellular atrophy of basal 
forebrain cholinergic neurons (BFCN). BFCN provide major 
projections to the cerebral cortex and the hippocampus and cortical 
cholinergic mechanisms are known to be directly involved in 
cognitive functions such as learning and memory [37]. NGF is 
synthesized by hippocampal and cortical neurons and is retro-
gradely transported to BFCN cell bodies [38-39]; it plays a key role 
in regulating survival and in maintaining the biochemical and 
morphological phenotype of adult BFCN [40-41]. BFCN in turn 
express both TrkA and p75 NGF receptors [38] and respond to 
administration of exogenous NGF by increasing phenotypic 
cholinergic markers [42]. Therefore, within the central cholinergic 
system, changes in NGF have been associated with age-dependent 
cognitive function and cognitive impairment following brain 
damage [43]. When a loss of NGF support occurs, cholinergic 
neurons show cell shrinkage, reduction in fiber density and down-
regulation of transmitter-associated enzymes (cholinoacetyl-
transferase-ChAT and acetylcholinesterase-AChE), thus resulting in 
a decrease of cholinergic transmission [44]. Investigations in the 
past decades have shown that administration of NGF to the BFCN 
in vitro leads to an increased survival and to an up-regulation of 
ChAT activity [45]. Furthermore, NGF infusion in aged rats 
ameliorates significantly deficits in spatial recent memory and to a 
minor extent also those concerning reference memory [40]; in 
addition, chronic intraventricular infusion of NGF has been 
demonstrated to restore long-term potentiation (LTP) deficits in old 
cognitively-impaired rats to levels equivalent to the control group 
[46]. Furthermore, the ability of NGF to prevent degeneration of 
BFCN has also been demonstrated in non-human primate brain 
[47]. 
 A severe cholinergic degeneration is also typical of AD, where 
a reduction of ChAT and AChE activity and BFCN size and 
number was observed [48-49]. This connection has provided a 
strong argument to link NGF and AD. Support for the role of NGF 
in AD was provided by knockout mice lacking both NGF and TrkA 
which showed large reductions in ChAT immunoreactivity in the 
basal forebrain and loss of cholinesterase activity in both the 
hippocampus and cortex [50]. A loss of the NGF receptor TrkA was 
found in the basal forebrain [51] and in the cortex [52] of AD 
brains. According to the hypothesis that NGF deprivation is one of 
the factors involved in the etiology of sporadic forms of AD, a 
mouse model (AD11 anti-NGF mice) had been developed, based on 
the expression of transgenic antibodies neutralizing NGF. The 
model is characterized by a progressive neurodegenerative pheno-
type defined by the deposition of amyloid peptide, by intracellular 
neurofibrillary tangles and by a marked cholinergic depletion [53]. 
In addition, spatial memory and neocortical LTP are impaired in 
AD11 mice at an age corresponding to early neurodegenerative 
stage. 
 Since changes of NGF concentrations have been reported in the 
course of different experimental disease models, there is evidence 
that endogenous NGF levels follow a distinctive temporal pattern 
[54-55]. Postmortem studies point to a lack of NGF action in early 
stages of AD [56], i.e. at the onset of neurodegeneration. In the 
majority of the neurodegenerative diseases, this reduction is 
followed by a raise of NGF concentration, which could be read as 
neuroprotective effort of counterregulation that should lead to 
adequate NGF levels in endangered NGF-dependent neurons. This 
hypothesis is supported by the fact that increased NGF concen-
trations were found in the hippocampus, cortical and subcortical 
regions of post-mortem AD brains [57], together with decreased 
NGF immunoreactivity in the basal forebrain [58]. These obser-
vations further suggest that there is a dysfunction in retrograde 
transport of NGF from the target tissues (hippocampus and neo-
cortical areas) to the BFCN cell bodies. In fact, axonal transport 
processes are essential in delivering the proper NTF signalling, 
mainly concerning survival effects. Whereas local effects induced 
by neurotrophins, such as the modulation of synapses, do not 
require the retrograde axonal transport of neurotrophins to the cell 
bodies, for survival effects neurotrophins must have the ability to 
transduce a series of complex signalling events from the nerve 
terminal plasma membrane to the nucleus located in the cell bodies. 
Most neurodegenerative dementias are linked to failures in axonal 
transport, i.e. defects in long-range neurotrophin signalling from 
distal axons to cell bodies. This led to the prediction that, more 
generally, failed axonal transport of NGF signals might provide a 
common link among reduction of NGF trophic support, cholinergic 
dysfunction and neurodegeneration [59].  
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 Interestingly, a novel way in which neurotrophins could 
contribute to neurodegeneration has been suggested. As previously 
reported, in addition to their effects on normal neuron function, 
NTFs and receptors have been proposed to contribute to the 
deleterious effects of old age and degenerative disease in the CNS 
[60]. Recent studies highlight how the precursor of neurotrophins 
may be either neurotoxic [61] or significantly less neurotrophic than 
its mature form [62]. Within this context, Al-Shawi et al. found 
age-associated increases in proNGF (the predominant form of NGF 
in the human and rodent brain) protein expression, as well as in 
sortilin protein, in the targets of neurons vulnerable to age-related 
neurodegeneration. These proNGF levels correlate positively with 
vulnerability to age-related neuronal cell death and proNGF-indu-
ced neurotoxicity appears to be mediated by sortilin [63]. However, 
understanding whether proNGF has adaptive roles in development 
and how its in vitro trophic effects are mediated needs further 
elucidation. 
 Altered levels of NGF have also been reported in other neuro-
degenerative disorders, such as PD (characterized by selective loss 
of nigral dopaminergic neurons) and ALS (characterized by a 
degeneration of the lower motor neurons in brain stem and spinal 
cord and the upper motor neurons in the cerebral cortex) as well as 
in diseases of abnormal excitability, such as epilepsy. Investigations 
in the past decades showed that, in substantia nigra and striatum of 
patients with PD, a small decrease in staining density for NGF has 
been observed [64]. Moreover, two studies on ALS found that 
mRNA and protein levels of NGF were increased [65-66]. More-
over, the levels of NGF mRNA were found increased in response to 
kindling as well as epileptic seizures in animal models of epilepsy 
[67]. Despite these observations, to date no human clinical trials 
have been performed with NGF in these diseases.  
NGF GENE-THERAPY  
 As opposed to PD and ALS, due to the efficacy in improving 
the survival and the maintenance of cholinergic neurons, the 
concept of therapeutic administration of human recombinant NGF 
in AD patients shows a strong rationale, being further validated by 
recent and ongoing clinical trials with a gene-therapy approach. 
Within this context, NGF gene therapy by Ceregene (CERE-110, 
the NGF gene in an adeno-associated virus [AAV]-based vector) 
has been tried in a phase I clinical study on eight patients with 
early-stage AD. This therapy, involving NGF-grafted autologous 
fibroblasts that are implanted in the basal forebrain, showed a 
slower progression of dementia, some cognitive improvement and 
sprouting of axons on the site of injection [68] (see Table 2). 
 Another study on the effect of intraventricular injections of 
NGF to AD patients showed some beneficial effects but also 
adverse side effects, such as weight loss and the induction of pain 
[69]. However, to date, because of poor pharmacokinetic profile 
and difficulties in the delivery of protein into the brain, the wide-
spread clinical application of gene or cell-therapy strategies for the 
delivery of NGF to AD patients seems unpractical, and it would be 
more advantageous to have non-invasive methods, that should also 
limit the adverse effects of NGF in activating nociceptive responses 
[68,70-71].  
NGF RECEPTOR MIMETICS 
 The development of small molecule neurotrophin receptor 
mimetics, or of NGF agonists in general, retaining the biological 
activity of the natural protein, was undertaken [72-73]. Until now 
the production of such drugs has required the mass screening of 
large libraries of synthetic chemicals. The approaches aiming to 
isolate small molecule mimetics are based on structural studies, 
starting from the tertiary structure of NGF, and comprise various 
types of compounds, most of them based on the search for an NGF 
mimetic able to induce an activation of the receptors, TrkA and/or 
p75 [73] (see text and Table 2). The recent findings of the 
increasing role of proNGF in neurodegeneration of the CNS 
through p75 receptor raise the possibility of targeting the p75 with 
small molecules, able to inhibit proNGF-induced cell death. One 
strategy is based on synthetic peptide mimetics of NGF loop 1, that 
could prevent cell death, since they seem to activate p75 and the 
downstream pathways involving NF?B and PI3K [72]. 
Furthermore, dimeric peptidomimetics based on the loop 4 on NGF, 
termed P92, were shown to act as partial NGF agonists, by inter-
acting with TrkA receptor and activating ERK and AKT signalling 
[74]. Recently, a new NGF-mimetic peptide, termed L1L4, was 
identified, by combining loop 1 and 4 in the same molecule [75]. 
This peptide was able to induce TrkA phosphorylation and diffe-
rentiation of PC12 cells, thus showing a good NGF-like activity in 
vitro, but showed the capability to reduce pain in an animal model 
of injury, which is inconsistent with the actions of NGF in 
neuropathic pain [76]; therefore, these data indicate that this 
compound is not yet ready for a clinical application. A different 
class of small molecules with NGF agonistic activity relies on the 
finding that the TrkA receptors can also be activated in the absence 
of neurotrophins, through transactivation by G-protein coupled 
receptor ligands (Table 2) [77-80]. To date, however, a better 
understanding of properties in vivo of these NGF agonists is 
required in order to evaluate their potential for the treatment of 
neurodegeneration. Moreover, it is worth to underline that some of 
these small molecule ligands have a mixed agonistic and anta-
gonistic profile, which makes it difficult to predict their behavior in 
vivo.  
NGF SYNTHESIS INDUCERS 
 Other strategies to increase the NGF neurotrophic support to the 
brain are based on the use of drug-releasing NGF biodegradable 
microspheres implanted into brain [81]. Furthermore, NGF syn-
thesis inducers, proNGF/NGF processing modulators and proNGF 
antagonists have also been investigated (see text and Table 3) [82-
87]. 
 It is interesting to notice that many of these pharmacological 
agents, recognized as modulators of NGF expression, have proven 
useful in the symptomatic treatment of neurodegenerative diseases. 
As an example, the AChE inhibitor Huperzine A, currently in Phase 
II clinical trial, increases NGF mRNA and protein levels after 
transient cerebral ischemia [82]. Xaliproden, a combined NGF 
potentiator and 5-HT1A receptor agonist, showed NGF effects in 
vitro and in vivo and delayed the progression of the motor neuron 
degeneration [83]. Ifenprodil, originally developed as an effective 
cerebral vasodilator, and then reported to act as an NR2B-selective 
NMDA receptor antagonist, has been shown to exhibit marked 
cytoprotective activities in animal models for focal ischemia and 
PD, strongly enhancing the production, besides other growth 
factors, of NGF [87]. Another possible approach consists in the 
identification of NGF processing modulators, able to interfere with 
the activity of proteases known to cleave proNGF, in order to act on 
the proNGF levels in disease states. However, due to the wide 
distribution of the proteases and their targets, a potential therapeutic 
intervention should be accurately designed in order to target the 
specific cellular populations affected in the disease [21,25]. Finally, 
in the framework of the investigation towards the use of the 
neurotrophin system in the therapeutic intervention for AD, another 
possibility could be based on the use of proNGF antagonists. In 
particular, the potential use of neurotensin as an antagonist for 
proNGF resides on the findings that the peptide competes with 
proNGF for the binding to sortilin [34]. However, the effects 
mediated by the binding of neurotensin to sortilin are presently not 
fully understood [88].  
BRAIN-DERIVED NEUROTROPHIC FACTOR-BDNF 
 BDNF, the second member of the neurotrophin family, is a 
small dimeric protein, which is abundantly expressed in the adult 
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Table 2. Classification of NTFs Gene-Therapy or Receptor Mimetics Currently in Research and Development, on the Basis of their 
Mode of Action and Indication. The Table has been Built on the Basis of the Search on the Site ClinicalTrial.gov (Consulted 
26 February 2009) and/or the Site(s) of the Producers 
Neurotrophic 
factor 
Molecole Profile of compound versus 
growth factor 
Indication  Pharmacological 
action 
Clinical 
phase 
Reference  
NGF NGF Adeno-virus delivered NGF AD  Phase I 68 
 P92 NGF agonistic activity AD Direct binding of 
TrkA receptor 
Preclinical 74 
 LIL4 NGF agonistic activity AD Direct binding of 
TrkA receptor 
Preclinical 75-76 
 Neotrofin (AIT-
082) 
NGF agonistic activity AD, memory disorders Analog of 
hypoxanthine 
Phase IB 77 
 Adenosine NGF agonistic activity AD, neurodegeneration, 
pain 
Transactivation by G-
protein coupled 
receptors  
Preclinical  78-79 
 N-PEP-12 NGF peptidomimetic AD, memory disorders Derivative of 
cerebrolysin 
Phase II 80 
BDNF BDNF Adeno-virus delivered BDNF PD, ALS  Preclinical  125 
GDNF GDNF Recombinant-methionyl human 
GDNF (Liatermin) 
PD  Phase I ClinicalTrial.
gov  
 GDNF Recombinant-methionyl human 
GDNF & Synchro Med 
Infusion System (continuously 
administered using chronically 
implanted catheters and pumps) 
Progressive 
Supranuclear Palsy 
 Phase II ClinicalTrial.
gov 
 XIB4035 GDNF receptor mimetic PD Direct binding of 
GFR?1 receptor 
Prelinical  176 
 
Neurturin Neurturin  Adeno-Associated Virus 
Serotype 2 [AAV2]-Neurturin 
PD  Phase II 185, 186 
ClinicalTrial.
gov 
Artemin Neublastin Recombinant human artemin Neuropathic pain Ligand for the Ret 
receptor 
Preclinical  187 
CNTF CNTF Implants of encapsulated 
human NT-501 cells releasing 
CNTF 
Retinitis Pigmentosa  Phase I 204 
 CNTF Implants of encapsulated 
human NTC-201 cells releasing 
CNTF 
Visual Acuity 
Impairment, 
Atrophic Macular 
Degeneration 
 Phase II 204 
IGF-1 Mecasermin 
(myotrophin) 
Recombinant  insulin-like 
growth factor-1   
AD  
ALS 
Direct binding of 
IGF-1R receptor 
Phase IIA 
Phase III 
224, 225 
231 
 Capromorelin  
(CP-424,391) 
Pyrazolinone-piperidine 
dipeptide growth hormone 
secretagogue 
Aging Agonist of the GH 
secretagogue receptor 
Phase II 228 
 IGF-1 Adeno-virus-delivered IGF-1 ALS  Preclinical  232 
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Table 3. Classification of Various Drugs having another Recognized Mechanism of Action as NTFs Synthesis Inducers. The Drugs 
Listed are Approved for Use or Currently in Research and Development and are Classified on the Basis of their mode of 
Action and Indication. The Table has been Built on the Basis of Available data Sheets of the Drugs Approved for Use and on 
the Search on the Site ClinicalTrial.gov (Consulted 26 February 2009) and/or the Site(s) of the Producers 
Neurotrophic 
factor 
Molecule Profile of compound 
versus growth factor 
Indication  Pharmacological action Clinical 
phase 
(*)
 
Reference  
NGF Huperzine A NGF synthesis inducer AD AChE inhibitor Phase II 81 
 Xaliproden 
(SR57746A) 
NGF synthesis inducer AD, ALS NGF potentiator and 5-HT1A 
receptor agonist 
Phase III 83 
 Selegiline NGF synthesis inducer PD Monoamine oxidase-inhibitor Approved  84 
 Rasagiline NGF synthesis inducer PD Monoamine oxidase-inhibitor Approved 85 
 CGP 36742 NGF synthesis inducer Neurodegeneration GABAB receptor antagonist Preclinical 86 
 CGP 56433A NGF synthesis inducer Neurodegeneration GABAB receptor antagonist Preclinical 86 
 CGP 56999A NGF synthesis inducer Neurodegeneration GABAB receptor antagonist Preclinical 86 
 Ifenprodil NGF synthesis inducer PD NR2B-selective NMDA receptor 
antagonist 
Preclinical 87 
 Imipramine  NGF synthesis inducer Depression  Tricyclic antidepressant  Approved 114 
BDNF Ifenprodil BDNF synthesis inducer PD NR2B-selective NMDA receptor 
antagonist 
Preclinical 87 
 Imipramine  BDNF synthesis inducer Depression  Tricyclic antidepressant  Approved 114 
 Fluoxetine  BDNF synthesis inducer Depression  Selective Serotonin Reuptake 
Inhibitor 
Approved  114 
 Tranylcypromine  BDNF synthesis inducer Depression  Irreversible monoamine oxidase 
Inhibitor 
Approved 114 
 Venlafaxine  BDNF synthesis inducer Depression  Serotonin and Noradrenaline 
Reuptake Inhibitor  
Approved 114 
 Memantine  BDNF synthesis inducer Moderate-severe 
AD 
NMDA receptor antagonist Approved 133 
 L-DOPA BDNF synthesis inducer PD Dopamine precursor Approved 134 
 Pramipexole  BDNF synthesis inducer PD, Restless Legs 
Syndrome 
D3 receptor agonist Approved 136 
 Ropinirole BDNF synthesis inducer PD D3 receptor agonist Approved 136 
 Apomorphine BDNF synthesis inducer PD D1/D2 receptor agonist Approved 137 
 Selegiline BDNF synthesis inducer PD Major 
Depression  
Monoamine oxidase-inhibitor Approved 
Phase III 
135 
138 
 Rasagiline BDNF synthesis inducer PD Monoamine oxidase-inhibitor Approved 85 
 SGS742 BDNF synthesis inducer AD GABAB receptor antagonist Phase II 139 
 Ladostigil 
(TV3326) 
BDNF synthesis inducer PD, AD Monoamine oxidase- and 
cholinesterase inhibitor 
Preclinical 140, 141 
 Ampalex 
(CX516) 
BDNF synthesis inducer AD/dementia AMPA receptor potentiator Phase II  ClinicalTri
al.gov 
 Biarylpropylsulfo
namides 
(LY392098, 
LY404187, 
LY503430) 
BDNF synthesis inducer PD, depression, 
CNS disorders 
AMPA receptor potentiator Preclinical  142 
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(Table 3) Contd…. 
 
Neurotrophic 
factor 
Molecule Profile of compound 
versus growth factor 
Indication  Pharmacological action Clinical 
phase 
(*)
 
Reference  
 Org24448 BDNF synthesis inducer Depression  AMPA receptor potentiator Phase II 143 
 Tacrolimus 
(FK506) 
BDNF synthesis inducer PD Immunosuppressive 
immunophilin ligand 
Preclinical  144, 145 
 GPI-1046 BDNF synthesis inducer PD Non-immunosuppressive 
immunophilin ligand 
Preclinical 144, 145 
 Tripchlorolide 
(TW397) 
BDNF synthesis inducer PD Chinese herbal compound 
(extract of Tripterygium wilfordii 
Hook F) 
Preclinical  146 
GDNF PYM50028 GDNF synthesis inducer PD 
AD 
Plant-derived compound obtained 
from a traditional Asian “tonic” 
Preclinical 
Phase II 
177 
ClinicalTri
al.gov 
 Tacrolimus 
(FK506) 
GDNF synthesis inducer PD Immunosuppressive 
immunophilin ligand 
Preclinical  145 
 GPI-1046 GDNF synthesis inducer PD Non-immunosuppressive 
immunophilin ligand 
Preclinical 145 
 Apomorphine GDNF synthesis inducer PD D1/D2 receptor agonist Approved 137 
 Pramipexole  GDNF synthesis inducer PD, Restless Legs 
Syndrome 
D3 receptor agonist Approved 136 
 Ropinirole GDNF synthesis inducer PD D3 receptor agonist Approved 136 
 Cabergoline  GDNF synthesis inducer PD D2/weak D1 agonist Approved 177 
 Selegiline GDNF synthesis inducer PD 
Major Depression  
Monoamine oxidase-inhibitor Approved  
Phase III 
135 
138 
 Rasagiline GDNF synthesis inducer PD Monoamine oxidase-inhibitor Approved 85 
 L-DOPA GDNF synthesis inducer PD Dopamine precursor Approved 178 
 Amantadine GDNF synthesis inducer PD 
HD 
 Approved 
Phase II 
179 
 Memantine  GDNF synthesis inducer Moderate-severe 
AD 
NMDA receptor antagonist Approved 179 
 Riluzole GDNF synthesis inducer ALS Na+ channel blocker Approved 180 
Amitriptyline GDNF synthesis inducer Depression, panic, 
social anxiety, 
generalized anxiety 
and obsessive-
compulsive 
disorder 
Noradrenaline and serotonin 
reuptake inhibitor 
Approved 181 
Clomipramine,  GDNF synthesis inducer Depression, panic, 
social anxiety, 
generalized anxiety 
and obsessive-
compulsive 
disorder 
Noradrenaline and serotonin 
reuptake inhibitor 
Approved 181 
 
Mianserine GDNF synthesis inducer Depression adrenergic alpha2-autoreceptors 
and alpha2-heteroreceptors 
antagonist, 5-HT2 and 5-HT3 
blocker 
Approved 181 
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Neurotrophic 
factor 
Molecule Profile of compound 
versus growth factor 
Indication  Pharmacological action Clinical 
phase 
(*)
 
Reference  
Fluoxetine GDNF synthesis inducer Depression, 
anxiety, obsessive-
compulsive 
disorder 
Selective Serotonin Reuptake 
Inhibitor 
Approved 181  
Paroxetine GDNF synthesis inducer Depression, 
anxiety, obsessive-
compulsive 
disorder 
Selective Serotonin Reuptake 
Inhibitor 
Approved 181 
(*) Clinical phase refers to the indication for which the molecule is currently in use or in development. 
 
mammalian brain. BDNF shares about 50% amino acid identity 
with NGF, NT-3 and NT-4 [89]. BDNF is abundantly expressed in 
the CNS, mainly in the hippocampal formation, cerebral cortex and 
amygdaloid complex [90]. Earlier efforts in NGF cellular biology 
showed that also BDNF is retrogradely transported by peripheral 
and CNS neurons; however, recent findings demonstrated that 
BDNF is also anterogradely transported in the CNS, a fact that has 
considerably expanded the concept of neuronal-derived trophic 
support [91]. BDNF expression increases until reaching a maximal 
level after birth [92] and then seems not to decline with age [93], 
thus suggesting essential roles for BDNF in the adult CNS. BDNF, 
through the interaction with its high-affinity receptor TrkB, is 
important for the survival and maintenance of different types of 
neurons and enhances neurogenesis. In particular, BDNF promotes 
the differentiation of neural progenitor cells into neurons and the 
survival of newly generated neurons [94]. In addition, BDNF is 
noteworthy for its role as a mediator of the effects of environmental 
factors on hippocampal neurogenesis. Levels of BDNF are 
increased in the hippocampus in response to exercise [95], dietary 
energy restriction [94] and cognitive stimulation [96], all of which 
stimulate neurogenesis. In the CNS, BDNF is also involved in 
synaptic plasticity, since its expression has been found increased in 
the hippocampus during learning-related events or after LTP 
induction [97-98]. In aged rats, conversely, both induction of 
BDNF by LTP and the associated signalling is decreased. However, 
the role of BDNF in the aging brain is discussed. There is evidence 
showing an increase in BDNF concentration in dentate gyrus from 
aged rats [99]. While, in other studies no changes in BDNF levels 
were found in rat hippocampus during the aging process, thus 
suggesting that rather alterations in BDNF receptors could occur 
during aging [100]. This speculation is reinforced by the past 
observations that BDNF administration did not counteract spatial 
learning impairments in aged rats [101].  
 In addition to its critical role in helping shape the vertebrate 
nervous system during development, BDNF is of particular 
therapeutic interest because of its neurotrophic actions on neuronal 
populations involved in several neurodegenerative diseases [102], 
including motor neurons, which degenerate in ALS [103], dopa-
minergic neurons of the substantia nigra, lost in PD, and BFCN 
involved in AD [104]. More recently, it has been demonstrated that 
BDNF probably plays a specific role in the etiology of HD [105]. 
 With respect to AD, BDNF is well known to be a regulator of 
synaptic function and synaptic plasticity as well as of BFCN and 
therefore its possible implication in AD is well grounded. BDNF is 
able to promote survival of BFCN [106] and directly stimulate, in 
these neurons, the release of acetylcholine [107], thus suggesting 
that deficits of BDNF synthesis could partecipate in disrupting the 
cellular homeostasis resulting in AD. A decreased expression of 
BDNF and its receptor TrkB has been found in postmortem regions 
from AD patients, thus suggesting a potential role for compromised 
neurotrophic support in neuronal susceptibility to AD. In particular, 
a decreased transcript abundance of BDNF mRNA was found in 
hippocampus and entorhinal cortex in AD brains [57,108]. Interes-
tingly, Murer et al. observed that neurons containing neurofibrillary 
tangles did not express BDNF, whereas neurons with no tangles 
expressed it, suggesting a possible protective role against 
neurofibrillary degeneration [109].  
 Other different lines of evidence point to a specific role for 
BDNF in the neuronal degeneration observed in PD. BDNF 
colocalizes with dopamine neurons in the substantia nigra, which 
are among the most prominent populations of neurons to degenerate 
in PD. In substantia nigra and striatum of patients with PD a small 
decrease in staining density for BDNF has been observed [110], 
underlining that reduced amount of this neurotrophin may be 
involved in the etiology and pathogenesis of PD. Interestingly, 
partial deletion of TrkB receptor induces a decreased number of 
neurons in the substantia nigra of old mice, together with a reduced 
expression of tyrosine hydroxylase and an increased formation of ?-
sinuclein deposits [111], thus suggesting that BDNF support is 
important for nigrostriatal dopaminergic neurons during sene-
scence.  
 Alteration in BDNF expression have also been reported in ALS, 
where one study found that mRNA and protein levels of BDNF 
were increased [66]. Also TrkB mRNA was upregulated in spinal 
cords from ALS patients [112]. Within neurodegenerative disor-
ders, a recent work implicated BDNF in HD as well [113]. Hun-
tingtin, the protein mutated in HD, upregulated BDNF transcription, 
and loss of huntingtin-mediated BDNF transcription led to loss of 
trophic support to striatal neurons, which subsequently degenerated 
in the hallmark pathology of the disorder [113]. In addition, a 
reduction in the level of BDNF protein has been observed in the 
striatum and cortex of transgenic mice overexpressing mutant 
huntingtin. Furthermore, in patients with HD, BDNF levels were 
found decreased by 45% in cortical brain tissue [113]. 
 Alterations in BDNF signalling may also be involved in mood 
disorders, such as depression, and in the mechanism of action of 
antidepressant drugs. A role for BDNF in the action of anti-
depressant treatments is supported by several lines of evidence. 
BDNF mRNA expression is decreased by stress in the hippo-
campus, whereas several antidepressant drugs are able to enhance it 
[114]. Compared with normal human subjects, levels of BDNF 
have been reported to be lower in postmortem brain tissue from 
depressed patients but higher in those taking antidepressants at the 
time of death [115]. Moreover, brain imaging studies have docu-
mented a reduction in hippocampal volume in depressed subjects, 
which can be attenuated by antidepressant treatment [116]. 
Interestingly, the implication of BDNF in mood disorders has been 
reinforced by a recent study of Pollak and coworkers [117]. They 
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recently suggested an animal model of a behavioral antidepressant, 
referred as learned safety, that shares some neuronal hallmarks of 
pharmacological antidepressants, as it increases the expression of 
BDNF in the hippocampus and also promotes the survival of 
newborn cells in the dentate gyrus of the hippocampus [117]. 
 Alterations in BDNF levels have also been involved in the 
pathogenesis of diseases of abnormal excitability, such as epilepsy 
and central pain sensitization, which is an activity-dependent 
increase in excitability of dorsal horn neurons resulting in a 
clinically intractable condition termed “neuropathic pain” [118]. 
Recent in vitro and in vivo findings implicated BDNF in the 
cascade of electrophysiologic and behavioural changes underlying 
the epileptic state. BDNF mRNA and protein are markedly 
upregulated in the hippocampus by seizure activity in animal 
models [67,114] and infusion of anti-BDNF agents [118] or trans-
genic truncated TrkB-overexpression [119] inhibit epileptogenesis 
in animal models. Conversely, overexpression of BDNF in trans-
genic mice leads to spontaneous seizures [120] and intrahippo-
campal infusion of BDNF is sufficient to induce seizure activity in 
vivo [121]. Moreover, BDNF may play an important neuro-
modulatory role in pain transduction [122]. BDNF is synthesized by 
dorsal horn neurons and markedly upregulated in inflammatory 
injury to peripheral nerves [123]. Electrophysiological and beha-
vioural data demonstrated that inhibition of BDNF signal 
transduction is able to inhibit central pain sensitization [124]. 
 Altogheter these data suggest an exciting potential for therapies 
aimed at replacing BDNF or otherwise mimicking its actions in 
these disorders.  
BDNF GENE-THERAPY 
 To date, a number of clinical trials investigated the therapeutic 
potential of BDNF, mainly in neurodegenerative disorders. With 
regard to PD, preclinical studies used AAV to deliver BDNF into 
brain; the injection into the substantia nigra was able to modulate 
locomotor activity without significantly affecting nigrostriatal 
dopaminergic survival [125] (see Table 2). Furthermore, the use of 
polymers with fibroblasts genetically engineered to produce BDNF 
has been tested in AD models [126]. However, no human studies 
with BDNF have been performed in PD, as well as in AD and HD 
patients. To date, human clinical trials with BDNF have only been 
performed in ALS, with disappointing results, due to the small 
number of patients and the contrasting results [127-129].  
BDNF RECEPTOR MIMETICS 
 The failure of clinical trials with recombinant BDNF is due to 
poor bioavailability, choice of an acceptable dosing regimen and 
difficulties in the delivery of protein into the brain; thus alternative 
ways to exploit BDNF actions for therapy are required. The 
development of small molecule BDNF peptidomimetic was and is 
currently undertaken [130-131]. Starting from the tertiary structure 
of BDNF, a tricyclic dimeric peptide was designed to mimic a 
cationic tripeptide sequence in loop 4 of BDNF that contributes to 
the binding of BDNF to the receptor p75. However, recombinant 
neurotrophin molecules acting through direct activation of the Trk 
receptors have shown disappointing results in many clinical trials 
[132]. It remains to be seen whether the currently available 
neurotrophin mimetics will result in drugs that effectively harness 
neurotrophin actions for therapeutic use. 
BDNF SYNTHESIS INDUCERS 
 Other strategies to increase the BDNF neurotrophic support to 
the brain are based on the use of BDNF synthesis inducers. Drugs 
clinically used to treat AD (memantine) [133], PD (L-Dopa, sele-
giline, rasagiline, pramipexole, ropinirole, apomorphine) [85,134-
137], depression [114,138] share the property to modulate BDNF 
levels in brain regions directly involved in the pathophysiology of 
the disease (see Table 3). As previously mentioned, ifenprodil can 
modulate expression of different NTFs, among which BDNF, thus 
suggesting the indication as a potential agent for the treatment of 
neurodegenerative disorders such as AD, PD and HD [87]. Among 
the drugs that are currently being tested in clinical trials for AD, the 
compound SGS742 gained interest, since, in addition to be a 
GABAB receptor antagonist, is able to stimulate BDNF synthesis 
[139]. Furthermore, the bifunctional drug ladostigil has been 
demonstrated to combine neuroprotective and cognitive enhancing 
effects in models of AD and PD [140-141]. Moreover, AMPA 
receptor modulators might be used to treat cognitive dysfunctions, 
since they potentiate the glutamatergic synaptic transmission that 
contributes to cognitive functions. A number of structurally unique 
AMPA receptor potentiators has been shown to enhance BDNF 
expression in vivo and to modulate synaptic function [142-143]. 
Within this group of molecules, CX516 and Org24448 are currently 
in clinical development for a number of CNS disorders, including 
depression, PD and AD (see Table 3).  
 Modulation of Trk receptor signalling cascades has been 
suggested as another therapeutic potential. Interestingly, the Trk 
receptor pathway can be directly enhanced by immunophilin 
ligands, which mediate their neurotrophic activity via the FK506-
binding proteins [144]. FK506 increased BDNF expression in 
mouse and human astrocyte cultures and striatal expression of 
BDNF and TrkB [145] putatively through binding to FKBP-52 with 
subsequent modulation of the Ras/Raf/MEK pathway. A similar 
effect was also observed in the presence of the non-immu-nosu-
ppressive immunophilin ligand GPI-1046 [145]. Finally, closely 
related to FK506, the immunosoppressive chinese herbal compound 
Tripchlorolide protected dopaminergic neurons in a PD model and 
stimulated an increase in BDNF expression [146]. However, since 
all the mentioned pharmacological interventions have other direct 
effects on neuronal signalling, in addition to modulate BDNF, more 
studies are needed to establish the precise relevance of their BDNF 
modulating activity to their systemic effect. 
GLIAL-CELL-DERIVED NEUROTROPHIC FACTOR 
FAMILY 
 GDNF family ligands are a group of polypeptides, structurally 
related to the TGF? superfamily, which are produced by target cells 
and have been implicated in survival and differentiation of several 
neuronal subpopulations in the developing nervous system. GDNF 
represents the first-studied member of this family and is involved in 
the neuritic outgrowth and survival of dopaminergic neurons of the 
substantia nigra, BFCN, brainstem noradrenergic neurons and 
Purkinje cells both in vitro and in vivo [21,147-148]. Besides 
GDNF, this family also includes neurturin, persephin and artemin. 
Neurturin (NRTN) is expressed and supports the survival of 
nigrostriatal neurons during development and adulthood [148], 
whereas persephin is involved in survival of motor and midbrain 
dopaminergic neurons [149]. Artemin (ART) is poorly expressed in 
fetal and adult human brain, but is present in the basal ganglia and 
thalamus. This member has been implicated in the maintenance and 
survival of sensory and sympathetic peripheral neurons [150]. Each 
of these members exerts its actions by interacting with specific 
receptors, thus triggering intracellular signalling cascades. The 
action of these NTFs on neurons is similar to that of the neuro-
trophins but with distinct differences. A common receptor binds all 
growth factors in the subfamily and a specificity receptor exists 
able to distinguish factors within the subfamily. In particular, 
GDNF family receptors (GFR) comprise a receptor complex 
composed by the Ret proto-oncogene product and one of the four 
subtypes of glycosyl phosphatidylinositol (GPI)-anchored co-
receptor GFR? (?1-?4). Each GDNF family member selectively 
activates one of four types of GFR? receptors thus leading to the 
activation of the Ret tyrosine kinase receptor. GDNF binds the 
GFR?1 receptor [151] and neurturin, persephin and artemin show a 
preference for GFR?2, GFR?3, GFR?4 respectively [21]. However, 
these binding specificities are not exclusive, since GDNF can bind 
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to GFR?2 and GFR?3, but with lower affinity, and then activate 
Ret [152]. 
GLIAL-CELL-DERIVED NEUROTROPHIC FACTOR-
GDNF 
 GDNF supports the development of embryonic dopamine 
neurons and is particularly important for postnatal survival of 
mesencephalic dopamine neurons [147]. It is present in the striatum 
and despite, being named glial-derived growth factor, may reside 
abundantly in the striatal medium spiny neurons receiving 
dopaminergic input from the substantia nigra [153]. GDNF and its 
receptors are also widely expressed in hippocampus from early 
embryonic ages to adulthood [154]. Furthermore, GDNF has been 
found in the human peripheral nerve axons and in Schwann cells 
[155]. By analogy with the neurotrophins, GDNF is subjected to 
retrograde transport, being internalized by distal axons and trans-
ported to the cell bodies [156]. However, little or no information is 
available yet about the mechanisms of retrograde signalling used by 
GDNF family. 
 GDNF binds to GFR?-1 leading to the activation of the receptor 
tyrosine kinase Ret [151]. This activation initiates many of the same 
signal transduction pathways elicited by other tyrosine kinase 
receptors, including the mitogen-activated protein kinases Erk-1 
and Erk-2 and the serine-threonine kinase Akt [157]. Through this 
signalling pathway, GDNF regulates the differentiation and survival 
of neurons by modulating the expression of antiapoptotic genes, 
such as Bcl-2, and others involved in neurotransmitter synthesis 
(such as tyrosine hydroxylase) [158-159]. In addition, a GDNF 
signalling independently of Ret has also been demonstrated. In the 
absence of Ret, GDNF has been shown to induce tyrosine 
phosphorylation of the MET receptor tyrosine kinase, as well as the 
activation of Fyn and FAK kinases [160-161], thus stimulating cell 
migration and neurite outgrowth. Noteworthy, several works 
demonstrated that GDNF contributes to synaptic transmission and 
can also play a role in learning and memory. GDNF increases the 
synaptic efficacy of dopaminergic neurons in culture by inducing 
new functional synaptic terminals [162]; recently a role for GDNF 
signalling in hippocampal synaptogenesis has been described [163]. 
 A role for GDNF in aging is based on the observations that it is 
able to reverse some aspects of aging in monkey [164]. Besides 
cognitive deficits, it is known that aging is also associated with 
impaired motor function, including reductions in movement speed 
and coordination. This decline is likely due to decreased dopa-
minergic trasmission in the basal ganglia, a brain region important 
for coordinating movements. GDNF has been demonstrated to 
modulate dopamine function in association with motor function 
recovery in animal models of aging and PD. In aged rhesus 
monkeys, GDNF was able to increase the size and number of 
substantia nigra neurons and the density of dopaminergic nerve 
fibers in the putamen [164-165]. Furthermore, it also restored 
dopaminergic axons in the striatum and improved MPTP (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) induced-parkinsonian beha-
vioral ratings [166]. Therefore, since its discovery in 1993, GDNF 
has been an attractive treatment option for PD due to its 
neurotrophic effects on dopaminergic neurons [167]. Moreover, the 
observations that GDNF is also a potent survival factor for spinal 
motoneurons also highlighted clinical implications for the treatment 
of ALS [168].  
 Concerning PD, current treatments provide only symptomatic 
relief and are unable to prevent the progressive death of neurons, 
besides to induce significant side effects. For these reasons, GDNF 
may represent an attractive therapeutic target for PD treatment. 
Many studies in animal models and some clinical trials in PD 
patients show that GDNF delivery can have trophic effects and 
restore motor function [169-170] (see Table 2).  
 
GDNF GENE-THERAPY 
 As previously reported, delivery of NTFs such as GDNF to the 
brain is problematic due to their inability to cross the blood-brain 
barrier, their brain diffusion and side-effects associated with 
binding to extra-target receptors. A possibility to overcome these 
limitations and at the same time to raise the concentration of 
therapeutic NTFs in a target tissue could be based on gene and cell-
therapy approach, namely viral vectors or the implantation of cells 
programmed to secrete the NTF of interest [171-172]. Within this 
context, human neural progenitor cells engineered to secrete 
GDNF, implanted into the striatum of rats, increased dopamine 
neuron survival and fiber proliferation [173]. 
GDNF RECEPTOR MIMETICS 
 Another potential choice to generate trophic actions in the CNS 
is based on small molecules capable of crossing the blood-brain 
barrier and directly stimulating receptors or transduction mecha-
nisms of NTFs [152] (see Table 2). For example, a small nonpep-
tide quinol, XIB4035, can bind to GFR?1, thus inducing a confor-
mational change responsible for GDNF receptor-Ret complex 
activation, and has been demonstrated to mimic neurotrophic 
effects of GDNF in Neuro-2A cells [174]. Furthermore, PYM-
50028, a novel non-peptide NTF inducer, increased striatal GDNF 
and attenuated the loss of dopaminergic neurons from the substantia 
nigra in MPTP-lesioned mice [175]. In addition, based on the fact 
that the blood-brain barrier is more permeable to immunophilin 
ligands than to NTFs, immunophilins are considered another 
promising treatment for neurodegenerative diseases. Besides 
BDNF, as previously reported, tacrolimus and GPI-1046 strongly 
enhanced also GDNF content in the mouse substantia nigra, but not 
in the striatum, when administered subcutaneously for 7 days, 
which suggests that the immunophilin ligand-induced neurotrophic-
like activity may be dependent on GDNF or BDNF expression 
[145]. 
GDNF SYNTHESIS INDUCERS 
 Finally, it is also interesting to underline that many drugs used 
in the symptomatic treatment of PD are recognized as modulators 
of GDNF expression, as well as of other neurotrophic factors (Table 
3). Since dopaminergic activity is able to promote GDNF 
expression (for a review see [176]) and the main characteristic of 
PD is the striatal dopamine deficit, drugs increasing dopaminergic 
transmission, such as dopamine receptor agonists (apomorphine, 
cabergoline, pramipexole and ropinirole) [136-137,177] or 
dopamine uptake and dopamine metabolism inhibitors (selegiline, 
rasagiline) [85, 135] have been demonstrated to induce GDNF 
expression in the nigrostriatal system (see Table 3). In contrast to 
the effect of dopamine agonists on GDNF expression, the effect of 
the dopamine precursor L-DOPA on GDNF levels in the nigro-
striatal system has not been extensively addressed. Only one study 
by Saavedra and coworkers demonstrated that L-DOPA can also 
induce GDNF up-regulation at the mRNA and protein levels in 
nigrostriatal system [178]. Finally, another drug used for the 
management of PD, the NMDA receptor antagonist amantadine, 
stimulated GDNF expression, which partially contributes to its 
neuroprotective properties observed in many in vitro and in vivo 
models [179].  
 Besides PD, also several drugs clinically used to treat AD 
(memantine) [179], ALS (riluzole) [180] and depression (amitrip-
tyline, clomipramine, mianserine, fluoxetine and paroxetine) [181] 
share the property to modulate GDNF levels in brain regions 
directly involved in the pathophysiology of the disease (see Table 
3). 
NEURTURIN AND ARTEMIN 
 Within the GDNF family, also NRTN and ART have gained in 
the last years particular attention. NRTN is a structural and 
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functional analog of GDNF that binds to GFR?2 receptors coupled 
to Ret [182]. NRTN has been shown to enhance survival of dopa-
minergic neurons both in vitro and in rodent and monkey models of 
PD [183-184]. In the latter studies, therapeutic administration of 
human recombinant NRTN into the striatum of the aged rhesus 
monkeys has been validated by recent and ongoing clinical trials 
with a gene-therapy approach. Within this context, NRTN gene 
therapy by Ceregene (CERE-120, an adeno-associated type 2 viral 
vector that encoded for human NRTN) is currently in phase II 
clinical trials [185] (see Table 2). Preclinical studies suggested that 
intrastriatal CERE-120 injection could induce neurturin expression 
in the rat striatum for at least 1 year. Postmortem examination also 
revealed an increase in tyrosine hydroxylase immunoreactivity in 
the injected striatum [186]. 
 ART has been shown to support the maintenance and survival 
of sensory and sympathetic peripheral neurons [150]. Recently, its 
potential application for the treatment of peripheral neuropathies 
has been proposed [187]. In fact, NsGene in Denmark and Biogen 
Idec in the United States are collaborating in the preclinical deve-
lopment of ART, termed neublastin, that has shown efficacy in 
animal models of neuropathic pain. Injections of the protein neu-
blastin promoted the regeneration of damaged sensory nerve cells 
and produced virtually complete long-term restoration of sensory 
and motor function [187]. These studies suggest neublastin has 
potential for further development as a treatment for traumatic nerve 
injury [132]. 
NEUROKINE FAMILY 
 The neurokine family includes several members: CNTF, 
interleukin-6, interleukin-11, leukemia inhibitory factor (LIF), 
oncostatin M, cardiotrophin-1 and granulocyte colony-stimulating 
factor, as reported in Table 1. All members are related to cytokines 
and show analogy concerning tertiary structure and signalling path-
ways through cell surface receptors, namely, leukemia-inhibitory 
factor receptor (LIFR) and gp130 [188-189]. Neurokines are 
involved in neuronal and glial differentiation and development, 
regulate both neuronal survival and phenotypic expression of 
neuropeptides and neurotransmitters and rescue neurons from 
axotomy-induced cell death [190].  
CILIARY NEUROTROPHIC FACTOR-CNTF  
 CNTF, originally identified as a survival-promoting activity for 
ciliary ganglion neurons in chick eye tissue [191], is the main 
member of neurokine family showing neurotrophic activity across a 
broad spectrum of peripheral and CNS cells, including parasym-
pathetic, sensory, sympathetic, motor, cerebellar, hippocampal and 
septal neurons. It is synthesized by astrocytes and acts as an auto-
crine and paracrine signal of astrocytic activation and hypertrophy 
in response to injury to CNS. In the periphery, CNTF is synthesized 
in muscle, released by motor neuron terminals and then 
retrogradely transported to cell bodies. The magnitude of transport 
is then increased by nerve lesion [192]. Of particular interest is the 
fact that CNTF partially prevents the atrophy of skeletal muscle 
following the formation of nerve lesions but has no effect on 
innervated muscle, suggesting that CNTF is primarily operative in 
the pathological state [193-194]. CNTF, structurally similar to the 
interleukin-6 family of hematopoietic cytokines, signals using 
common cytokine receptor components [195]. CNTF binds to the 
GPI-anchored alpha subunit of the CNTF receptor complex 
(CNTFR?) which induces the recruitment of two transmembrane 
receptor proteins gp130 and LIFR?, resulting in tyrosine phos-
phorylation and the downstream activation of the Janus kinase/ 
signal transducer and activator of trancription (JAK/STAT) 
signalling pathway [196-197]. STAT proteins then translocate to 
the nucleus where they bind specific DNA sequences resulting in 
the transcription of responsive genes. 
 Since CNTF protein is mainly expressed in glial cells of 
peripheral nerve system and in CNS, it has been involved in several 
cerebral processes, such as cells fate determination of neural stem 
cells and neuronal and glial differentiation and development [196]. 
Concerning this action, the existence of a crosstalk between NTFs 
has been reported. In particular, CNTF and BDNF showed 
synergistic effects on the development and survival of multiple 
populations of neurons [197]; as example, CNTF was able to 
potentiate BDNF-induced cell survival of BFCN when added 
concomitantly [198]. Furthermore, CNTF has been implicated in 
the regulation of post-injury processes, since its levels strongly 
increased after injury in both peripheral and central neurons [196]. 
Noteworthy, recent data suggest a link among CNTF, neurogenesis 
and dopamine, based on the observation that CNTF enhances 
forebrain neurogenesis in adult mice and is expressed in astrocytes 
in the subventricular zone, a brain area where dopaminergic 
nigrostriatal projections regulate neural precursor cell proliferation 
[199]. This link has been reinforced by a series of in vivo and in 
vitro experiments that implicate CNTF as an endogenous regulatory 
component of dopamine D2-receptor-dependent neurogenesis in the 
subventricular zone and the dentate gyrus of the hippocampus 
[200]. Since an imbalance in dopaminergic signalling is a patholo-
gical hallmark of several neurological diseases, such as PD, HD and 
ALS, and CNTF supported survival of neurons both in vivo and in 
vitro models of neurodegeneration [196], pharmacologically 
modulating CNTF may be proposed as an attractive therapeutic 
strategy for normalizing dopaminergic and neurogenic deficits. 
However, previous attempts to use CNTF as a therapeutic agent in a 
variety of therapeutic areas yielded disappointing results. As 
example, Axokine, a modified version of human CNTF with a 15 
amino acid truncation of the C-terminus and two amino acid 
substitutions, which make it three to five times more potent and 
stable than CNTF in in vitro and in vivo assays, was tested in the 
1990s as a treatment for ALS. Systemic delivery of recombinant 
CNTF failed to achieve sufficient concentrations in the brain, 
leading to poor efficacy, while producing adverse effects, such as 
weight loss. Although initially discouraging, to date, CNTF has 
shown some recent promise in early-stage clinical trials for HD and 
neurodegenerative retinal diseases [201-204] (see Table 2). 
NON-NEURONAL GROWTH FACTORS 
 Several NTFs have been recognized to be expressed by non 
neuronal cells. Non-neuronal growth factors are expressed in large 
concentration in the nervous system and include acidic fibroblast 
growth factor (aFGF or FGF-1), basic fibroblast growth factor 
(bFGF or FGF-2), epidermal growth factor (EGF) and insulin-like 
growth factors (IGFs). Concerning its potential in human clinical 
trials for treatment of ALS, we will focus on IGF-1, whose role as 
trophic and survival factor for nervous system has been reported. 
INSULIN-LIKE GROWTH FACTOR-1-IGF-1 
 IGF-1 is a member of IGFs, a family of peptides with high 
sequence similarity to insulin, playing important roles in 
mammalian growth and development [205]. IGF-1 is predominantly 
formed in the liver after stimulation by circulating growth hormone 
(GH) and released by the pituitary gland; it is also synthesized in 
low concentrations in most peripheral tissues, including bone, 
cartilage and skeletal muscle. In the nervous system, IGF-1 and its 
receptors are expressed specifically in the substantia nigra [206], 
both in glial cells and in neurons [207]. IGF-1 was initially 
described as a growth mediating factor regulated in the context of 
the somatotrophic axis, acting through both autocrine and paracrine 
mechanisms in order to stimulate cell growth and differentiation of 
peripheral tissues and contributing to normal somatic growth [208]. 
IGF-1 has also acute insulin-like metabolic effects [209], increases 
glucose and amino acid uptake, stimulates mRNA and protein 
synthesis in cells and, as insulin, prevents apoptosis [210]. Note-
worthy, during the last decade, IGF-1 has gained particular atten-
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tion also for its role in the regulation of lifespan and brain functions 
[211]. IGF-1 mediates its effects by binding the extracellular ?-
subunits of the receptor IGF-1R and triggers a conformational 
change in the ?-subunit, resulting in its trans-autophosphorylation 
in multiple tyrosine residues. This event allows recognition and 
further tyrosine phosphorylation of phosphotyrosine-binding 
domains of adaptor proteins (for a review see [212]), that transduce 
signal to multiple response downstream pathways, such as phos-
phatidylinositol-3-kinase, mitogen-activated protein kinase and 
FOXO pathways [213].  
 It is known that aging is characterized by a significant decline 
of metabolic and hormonal functions, which often facilitates the 
onset of severe age-associated pathologies. Recent evidence support 
the involvement of IGF-1 signalling in neuroprotection [214], in the 
control of aging and longevity [215], in ALS and in the 
development of late-onset forms of AD [27, 216]. In this context, 
data from literature show that insulin and IGF-1 have a direct effect 
on the metabolism and clearance of beta-amyloid and also influence 
the development of neurofibrillary tangles, the known hallmarks of 
AD brain [217-220]. Moreover, Araki and collegues recently 
demonstrated that IGF-1 may promote beta-amyloid production 
through a secretase-indipendent mechanism [221]. However, under-
standing whether IGF-1 has a specific crucial role in the modulation 
of beta-amyloid production still needs further elucidation. In 
addition to a direct effect of IGF-1 on AD pathology, it has also 
well documented neuroprotective effects [222] and promotes 
neurogenesis [223], development, differentiation, synapse for-
mation and glucose utilization throughout the brain.  
 On this basis, IGF-1 may be candidate for a therapeutic 
approach. Currently some clinical studies are investigating its 
potential therapeutic role in aging and in patients affected by AD 
and mild cognitive impairment (see Table 2). In this regard, a study 
with recombinant IGF-1 has been recently approved to verify its 
neuronal protective action in patients with AD and mild cognitive 
impairment [224], based on previous data that indicate that IGF-1 
levels inversely correlate with cognitive impairment [225]. 
Concerning the potential use of IGF-1 in aging, a good promise is 
represented by a pyrazolinone-piperidine dipeptide derivative, 
capromorelin (CP-424,391), an investigational medication able to 
act as a GH secretagogue (Table 2). Preliminary studies have shown 
the drug to directly raise IGF-1 and GH levels [226-227]. To date, 
the drug is being considered for its therapeutic value in aging 
because elderly people have much lower levels of GH and less lean 
muscle mass, which can lead to weakness and frailty [228]. IGF-1 
analogs are also interesting optional compounds and their efficacy 
has been tested with promising results in a model of ischemia [229], 
thus highlighting IGF-1 signalling pathway as a promising thera-
peutic target for the treatment of neurodegenerative disorders. In 
particular, greater advances on the potential use of these com-
pounds have been reported in ALS. Mecasermin (myotrophin), an 
analogue of the IGF-1, had been shown to promote neurite 
outgrowth in culture and to be upregulated in the spinal cord of 
patients with ALS [230]. Mecasermin is at the moment in a phase 
III clinical trial in order to evaluate its benefit in slowing the 
progression of weakness in ALS, by promoting muscle re-
innervation, axonal growth and regeneration. However, after a 2-
year treatment period, disappointing results have been reported 
[231]. The failure of these clinical trials with IGF-1 analogs is 
mainly due to poor bioavailability and difficulties in the delivery of 
protein into the brain; thus alternative ways to exploit IGF-1 actions 
for therapy are required. AAV engineered to contain the gene for 
IGF-1 may be an option for a targeted delivery of IGF-1 to motor 
neurons, since, after intramuscolar injection, the gene vector is 
transported to the neuronal cell body by retrograde axonal transport 
along motor neurons [232]. However, human safety, dose schedule, 
and pharmacokinetics have not yet been established for this novel 
gene therapy. A small phase II trial of AAV engineered to contain 
the gene for IGF-1 is planned for the near future [233].  
NEUROTROPHIC FACTORS AND THE CROSSTALK 
BETWEEN INFLAMMATION AND NEURODEGENE-
RATION 
 In recent years, several functions of NTFs beyond the nervous 
system have been described. Several data on NTFs role on the 
immune system and on models of autoimmune demyelination, such 
as experimental autoimmune encephalomyelitis (EAE) have been 
reported and, in particular, we focused on the functions of some 
neurotrophins (NGF and BDNF) and CNTF.  
 NGF regulates a variety of immune functions; it is involved in 
proliferation, differentiation and antibody synthesis of B cells, in 
proliferation and expression of cytokine receptors in T cells and in 
chemotaxis of macrophages and neutrophils [234-236]. BDNF may 
play a role in the innate and adaptive immune system. This neuro-
trophin is expressed in primary and secondary lymphoid organs and 
is found in T and B cells, in monocytes [237] as well as in 
granulocytes, bone marrow cells [238] and mast cells [239], even if 
the physiological relevance of its expression in some of these cell 
types has not been fully elucidated yet. Furthermore, both NGF and 
BDNF have been found to play a role in the activation of bronchial 
eosinophils and the regulation of eosinophilic inflammation in 
allergic asthma [240-241]. Also some hints concerning an 
interaction between CNTF and the immune system may be made 
based on the observation that CNTF may promote an acute-phase 
response in the liver when administered peripherally [242], an 
adverse effect that limits its clinical application. Regarding CNTF, 
recent data from literature showed its ability to interact with the 
immune system in autoimmune demyelination [243-244]. In 
particular, when administered intraperitoneally, CNTF inhibited 
inflammation in the spinal cord, thus ameliorating the clinical 
course of EAE during time of treatment. In addition to CNTF, 
several studies also investigated the role of NGF and BDNF in 
autoimmune demyelination. In particular, an upregulation of NGF 
in glial cells during EAE and in the cerebrospinal fluid in patients 
affected by multiple sclerosis has been reported [245], whereas the 
exogenous application of human NGF delayed the onset of EAE 
and decreased the extent of EAE lesions [246]. Also BDNF 
secretion of immune cells and serum from patients with multiple 
sclerosis was found increased [247], even if these data were not 
always reproduced [248], and the application of BDNF-transduced 
bone marrow stem cells was able to reduce the course of EAE and 
inflammatory infiltration in the spinal cord [249].  
 As previously reported, during aging a fragile balance between 
NTFs support and dysfunction occurs, which may be at the base of 
the link between inflammation and neurodegeneration [250]. It has 
been postulated that the activation of the immune system is 
different and dependent on a discordant brain inflammatory res-
ponse in aged compared with younger organisms [251]. The aging 
brain is characterized by a shift from the homeostatic balance of 
inflammatory mediators to a proinflammatory state. This increase in 
neuroinflammation is marked by increased numbers of activated 
and primed microglia, increased steady-state levels of inflammatory 
cytokines and decreases in anti-inflammatory molecules. These 
conditions sensitize the aged brain to produce an exaggerated 
response to the presence of an immune stimulus in the periphery or 
following exposure to a stressor [252]. Therefore, accumulation of 
proinflammatory cytokines during aging has been hypothesised to 
lead to a “neurotrophin resistance” state that places the brain at risk 
for cognitive decline and neurodegenerative diseases [253]. Within 
this context, strategies to overcome cellular resistance to NTFs 
signaling are strongly required. One attempt was made in order to 
counteract the accumulation of pro-inflammatory cytokines. Tumor 
necrosis factor alpha (TNF-?) is an immunomodulating cytokine 
promoting acute-phase reactions and, when chronically elevated, 
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can induce degenerative changes. In the context neuroinflam-
mation/neurodegeneration, TNF-? is able to increase interleukin-1 
expression, in turn involved in production of the precursors 
necessary for formation of hallmarks of neurodegenerative diseases, 
such as amyloid plaques, neurofibrillary tangles and Lewy bodies 
[254]. A number of reports have recently been published regarding 
an experimental treatment for AD by using the anti TNF-? 
antibody, etanercept [255-257]. In particular, the case report by 
Tobinick demonstrated that perispinal administration of etanercept, 
a large molecule unable to cross the blood brain barrier following 
conventional systemic administration, may provide a rapid and 
sustained improvement in cognitive function for six months in 
patients with mild, moderate and severe AD [256]. Such rapid gain 
of function led to speculate that this drug may be able to counteract 
gliotransmission or other equally rapid synaptic events in the 
human brain [258]. Moreover, this treatment approach utilizes 
therapeutic delivery of etanercept across the dura via the cere-
brospinal venous system and may suggest the possibility that 
perispinal delivery of other biologics, such as vascular endothelial 
growth factor antagonists, interleukin antagonists, or NTFs, might 
be useful for the treatment of additional neurodegenerative 
disorders. However, the use of this anti TNF-? antibody to treat AD 
and the way these studies were conducted is still controversial and 
requires further investigation. Human data demonstrating that 
etanercept reaches either the cerebrospinal fluid or the central 
nervous system in sufficient concentrations to inhibit the action of 
TNF when administered perispinally and any placebo-controlled 
data are to date missing. The latter would test whether any response 
is due to the drug or to something else associated with the proce-
dure. Furthermore, some criticisms also concern the reported 
rapidity of response which is still to be proved mechanistically 
when considering the time required for resolution of an active 
inflammatory response and the potential impact that this could have 
on cognition.  
NEUROTROPHIC FACTORS-BASED THERAPY AND 
RELATED MECHANISMS 
 Normally, regulation of NTFs signalling is under exquisite 
control. However, the presence of an altered availability of NTFs or 
one of their dependent kinases may affect the regulation of neuronal 
survival and behavior thus resulting in the onset of neurode-
generative cascades contributing to aging as well as to the 
pathogenesis of diseases. In the adult central nervous system 
affected by age or disease-related degeneration, mechanisms of 
compensation and repair are activated in an attempt to counteract 
functional sequelae of neuronal loss [259-260]. As a consequence, 
degenerative events become manifest as a disorder only after 
exceeding a critical threshold, thereby exhausting the capacity of 
compensation [261]. However, it is worth to highlight that, under 
certain conditions, these compensational processes might be 
maladaptive and eventually even contribute to the development and 
progression of the disease. This seems to be the situation in AD, 
where an aberrant dendritic growth is observed instead of the 
regular dendritic growth seen during aging and in a variety of 
related degenerative disorders [262-263]. 
 When considering NTFs network, one attempt is represented by 
compensating the missing component. However, it is worth to 
underline that in a biological network the altered availability of a 
component leads in turn to modify its cellular interplay. In fact, 
regulatory mechanisms are activated. As an example, several 
biological mechanisms may take part in neural-level synaptic modi-
fications that self-regulate neuronal activity; these include receptor 
up-regulation and downregulation [264], activity-dependent 
regulation of membranal ion channels [265], and activity-dependent 
structural changes that reversibly enhance or suppress neuritic 
outgrowth [266]. These observations in turn suggest that in a 
system with altered ratios the simple substitution theraphy is not  
 
appropriate and this may in part explain why NTFs integration 
alone to prevent aging and treat neurodegenerative disorders is to 
date not totally effective. To better clarify, as an example, the 
model of stroke can be considered, where an increased knowledge 
of the complex pathophysiology has been reached due to the great 
availability of animal models [267]. In stroke, a neuroprotective 
intervention points at inhibiting a cascade of pathological molecular 
events occurring under ischaemia and resulting in calcium influx, 
activation of free radical reactions and cell death. To date, in human 
stroke trials, the use of a single agent has been unable to prove a 
clinically valuable effect, because treatment has often been initiated 
much later than in successful experimental stroke models, and 
because of insufficient doses or low availability of the drug at the 
target area. Hence, as future new approach, a combination of 
neuroprotective agents should be strongly proposed to address 
several of the compromised mechanisms [268].  
CONCLUSIONS/PERSPECTIVES 
 Restricted availability of NTFs is critical in the developmental 
regulation of neuronal survival and behavior and can set the stage 
for neurodegenerative cascades contributing to aging as well as to 
the pathogenesis of diseases. To date a question is still debated: Is 
there a future for NTFs in preventing aging and in the treatment of 
neurodegenerative diseases? The simple answer based on data here 
presented, in particular on gene-therapy and NTFs mimetics, would 
be “no”, but this seems premature in view of the fact that the 
research is still in its infancy. The ability to promote endogenous 
repair through the use of targeted growth factor delivery is an 
attractive approach. In addition, the development of small 
molecules that specifically activate NTFs receptor and can be 
administered systemically could represent a valid option, since it 
would overcome most of the problems associated with the delivery 
of NTFs into the brain, with their expression induced by viral 
vectors, or with the use of encapsulated growth factors producing 
cells. Although animal and human studies provide hope for the 
therapeutic application of NTFs or mimetic molecules, they also 
indicate that further studies are needed to optimize therapeutic 
effects and minimize adverse effects. As with all pharmacological 
manipulations, it is known that an excess neurotrophic stimulation 
(or an improper localization of the stimulation) can result in 
deleterious adverse effects. For example, patients reported pain at 
NGF injection sites, putatively as the result of abnormal local nerve 
sprouting [269]. Side effects may also result from the fact that 
growth factors can also affect non-neuronal cells. NGF adminis-
tration induces Schwann cells hyperplasia in vivo [270]. BDNF 
stimulates oligodendrocyte proliferation during axonal regeneration 
[271], whereas NGF kills cultured mature oligodendrocytes via a 
p75-mediated mechanism [272]. Furthermore, cardiovascular side 
effects or angiogenesis [273] could occur after NTFs systemic 
application, since they also play a role in the development and 
maintenance of large blood vessels [274]. Finally, growth factors 
can also promote the survival, proliferation and metastasis of many 
tumor subtypes. These potential disadvantages to the development 
of molecules that promote neurotrophic function suggest that ideal 
compounds would work in synergy with existing NTF molecules 
and enhance rather than directly stimulate neurotrophic activity. 
 In addition, another point has to be considered, namely that 
therapeutic benefit may be dependent on the extent of neuro-
degeneration before therapy initiation. Thus, within this context, 
although studies will be difficult, assessment of the effects of NTFs 
on the rate of progression over longer time frames could probably 
be critical in determining their ultimate efficacy. 
 Therefore, while critically reflecting on the new trials result, 
much has still to be learnt about the useful application of NTFs and 
to abandon it at this stage could be premature. 
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ABBREVIATIONS 
AAV = Adeno-Associated Virus 
AChE = Acetylcholinesterase 
AD = Alzheimer’s disease 
aFGF = Acidic Fibroblast Growth Factor 
ALS = Amyotrophic Lateral Sclerosis  
ART = Artemin  
BDNF = Brain-Derived Neurotrophic Factor  
BFCN = Basal Forebrain Cholinergic Neurons  
bFGF = Basic Fibroblast Growth Factor 
ChAT = Cholinoacetyltransferase 
CNTF = Ciliary Neurotrophic Factor 
EAE = Experimental Autoimmune Encephalomyelitis  
EGF = Epidermal Growth Factor  
GDNF = Glial-cell-line-Derived Neurotrophic Factor  
GFR = GDNF Family Receptors  
GH = Growth Hormone  
GPI = Glycosyl Phosphatidylinositol  
HD = Huntington’s disease  
5-HT = Serotonin 
IGF-I = Insulin-like Growth Factors I 
IGFs = Insulin-like Growth Factors  
LIF = Leukemia Inhibitory Factor  
LIFR = Leukemia Inhibitory Factor Receptor 
LTP = Long-Term Potentiation 
MPTP = 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine 
NGF = Nerve Growth Factor  
NRTN = Neurturin 
NT-3 = Neurotrophin-3  
NTFs = Neurotrophic Factors  
PD = Parkinson’s disease  
TGF = Transforming Growth Factor  
TNF = Tumor Necrosis Factor  
Trk = Tyrosine Receptor Kinase  
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